{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:47Z","timestamp":1792093787773,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12020-021-02766-2","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T12:03:28Z","timestamp":1622030608000},"page":"146-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil"],"prefix":"10.1007","volume":"74","author":[{"given":"Karina Zanlorenzi Basso","family":"Manosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Labigalini","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximene","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica R.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-7941","authenticated-orcid":false,"given":"Cesar Luiz","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"issue":"1","key":"2766_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ecl.2007.10.002","volume":"37","author":"MS Ben-Shlomo","year":"2008","unstructured":"M.S. Ben-Shlomo, Acromegaly. Endocrinol. Metab. Clin. N. Am. 37(1), 101\u201322 (2008). viii","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"issue":"2","key":"2766_CR2","doi-asserted-by":"publisher","first-page":"T141","DOI":"10.1530\/JOE-15-0109","volume":"226","author":"C Capatina","year":"2015","unstructured":"C. Capatina, J.A.H. Wass, 60 Years of neuroendocrinology: acromegaly. J. Endocrinol. 226(2), T141\u2013160 (2015)","journal-title":"J. Endocrinol."},{"issue":"5","key":"2766_CR3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509\u20131517 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2766_CR4","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski, M. Bolanowski, V. Bonert, M.D. Bronstein, F.F. Casanueva, D. Clemmons, A. Colao, D. Ferone, M. Fleseriu, S. Frara, M.R. Gadelha, E. Ghigo, M. Gurnell, A.P. Heaney, K. Ho, A. Ioachimescu, L. Katznelson, F. Kelestimur, J. Kopchick, M. Krsek, S. Lamberts, M. Losa, A. Luger, P. Maffei, M. Marazuela, G. Mazziotti, M. Mercado, P. Mortini, S. Neggers, A.M. Pereira, S. Petersenn, M. Puig-Domingo, R. Salvatori, I. Shimon, C. Strasburger, S. Tsagarakis, A.J. van der Lely, J. Wass, M.C. Zatelli, S. Melmed, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Edocrinol Metab. 105(4), e937\u2013946 (2020)","journal-title":"J. Clin. Edocrinol Metab."},{"issue":"2","key":"2766_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble, Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89(2), 667\u201374 (2004)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2766_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4158\/EP.17.4.636","volume":"17","author":"L Katznelson","year":"2011","unstructured":"L. Katznelson, J.L. Atkinson, D.M. Cook, S.Z. Ezzat, A.H. Hamrahian, K.K. Miller, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20142011 update: executive summary. Endocr. Pract. 17(4), 636\u2013646 (2011)","journal-title":"Endocr. Pract."},{"issue":"7","key":"2766_CR7","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141\u20138 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"2766_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A Consensus Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2018)","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"2766_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","volume":"19","author":"A Colao","year":"2016","unstructured":"A. Colao, R. Auriemma, R. Pivonello, L. Kasuki, M.R. Gadelha, Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19(3), 235\u201347 (2016)","journal-title":"Pituitary"},{"issue":"4","key":"2766_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1210\/jc.2007-2104","volume":"93","author":"O Alexopoulou","year":"2008","unstructured":"O. Alexopoulou, M. Bex, R. Abs, G. T\u2019Sjoen, B. Velkeniers, D. Maiter, Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J. Clin. Endocrinol. Metab. 93(4), 1324\u201330 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"2766_CR11","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1210\/jc.2005-0260","volume":"90","author":"PU Freda","year":"2005","unstructured":"P.U. Freda, L. Katznelson, A.J. van der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90(8), 4465\u20134473 (2005)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"2766_CR12","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"J.D. Carmichael, V.S. Bonert, M. Nu\u00f1o, D. Ly, S. Melmed, Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments\u2014a metaanalysis. J. Clin. Endocrinol. Metab. 99(5), 1825\u20131833 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2766_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32(2), 247\u2013271 (2011)","journal-title":"Endocr. Rev."},{"issue":"5","key":"2766_CR14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/cen.13129","volume":"85","author":"GA Kanakis","year":"2016","unstructured":"G.A. Kanakis, A. Chrisoulidou, A. Bargiota, Z.A. Efstathiadou, L. Papanastasiou, A. Theodoropoulou, S.K. Tigas, D.A. Vassiliadi, S. Tsagarakis, M. Alevizaki, The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis. Clin. Endocrinol. 85(5), 681\u2013688 (2016).","journal-title":"Clin. Endocrinol."},{"issue":"2 Feb","key":"2766_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/jc.2008-1371","volume":"94","author":"JD Carmichael","year":"2009","unstructured":"J.D. Carmichael, V.S. Bonert, J.M. Mirocha, S. Melmed, The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J. Clin. Endocrinol. Metab. 94(2 Feb), 523\u20137 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2766_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","volume":"138","author":"S Frara","year":"2016","unstructured":"S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, The modern criteria for medical management of acromegaly. Prog. Mol. Biol. Transl. Sci. 138, 63\u201383 (2016).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"2","key":"2766_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1365-2265.2009.03556.x","volume":"71","author":"PU Freda","year":"2009","unstructured":"P.U. Freda, Monitoring of acromegaly: what should be performed when GH and IGF-I levels are discrepant?. Clin. Endocrinol. 71(2), 166\u201370 (2009).","journal-title":"Clin. Endocrinol."},{"issue":"7","key":"2766_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1590\/S0004-27302011000700006","volume":"55","author":"D Fedrizzi","year":"2011","unstructured":"D. Fedrizzi, T.C. Rodrigues, F. Costenaro, R. Scalco, M.A. Czepielewski, Hypertension-related factors in patients with active and inactive acromegaly. Arq. Bras. Endocrinol. Metab. 55(7), 468\u201374 (2011).","journal-title":"Arq. Bras. Endocrinol. Metab."},{"issue":"1","key":"2766_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5603\/EP.a2018.0080","volume":"70","author":"M Elbaum","year":"2019","unstructured":"M. Elbaum, \u0141. Mizera, M. Bolanowski, The real costs of acromegaly: analysis of different therapies. Endokrynol. Pol. 70(1), 74\u201385 (2019)","journal-title":"Endokrynol. Pol."},{"issue":"3","key":"2766_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3171\/2012.4.JNS11739","volume":"117","author":"NF Marko","year":"2012","unstructured":"N.F. Marko, E. LaSota, A.H. Hamrahian, R.J. Weil, Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J. Neurosurg. 117(3), 522\u201338 (2012)","journal-title":"J. Neurosurg."},{"issue":"11","key":"2766_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/BF03345306","volume":"27","author":"G Didoni","year":"2004","unstructured":"G. Didoni, S. Grottol, V. Gasco, M. Battistini, D. Ferone, M. Giusti, F. Ragazzoni, P. Ruffo, E. Ghigo, F. Minuto, Cost-of-illness study in acromegalic patients in Italy. J. Endocrinol. Investig. 27(11), 1034\u20139 (2004)","journal-title":"J. Endocrinol. Investig."},{"issue":"4","key":"2766_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/11599680-000000000-00000","volume":"32","author":"M Roset","year":"2012","unstructured":"M. Roset, S. Merino-Montero, M. Luque-Ram\u00edrez, S.M. Webb, P. L\u00f3pez-Mond\u00e9jar, I. Salinas, A. Soto, C. Bernal, C. Villabona, D. De Luis, S. Donnay, H. Pascual, J. P\u00e9rez- Luis; Spanish group of the OASIS study, Cost of clinical management of acromegaly in Spain. Clin. Drug Investig. 32(4), 235\u201345 (2012)","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"2766_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/EJE-16-0623","volume":"176","author":"E Les\u00e9n","year":"2017","unstructured":"E. Les\u00e9n, D. Granfeldt, A. Houchard, J. Dinet, A. Berthon, D.S. Olsson, I. Bj\u00f6rholt, G. Johannsson, Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur. J. Endocrinol. 176(2), 203\u2013212 (2017)","journal-title":"Eur. J. Endocrinol."},{"key":"2766_CR24","unstructured":"CONITEC (Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS): Pegvisomanto para acromegalia. Report no. 348 (2018)"},{"issue":"3","key":"2766_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11102-011-0335-y","volume":"15","author":"Y Tutuncu","year":"2012","unstructured":"Y. Tutuncu, D. Berker, S. Isik, U. Ozuguz, G. Akbaba, F.K. Kucukler, Y. Aydin, S. Guler, Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 15(3), 398\u2013404 (2012)","journal-title":"Pituitary"},{"issue":"2","key":"2766_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1365-2265.2005.02317.x","volume":"63","author":"RS Jallad","year":"2005","unstructured":"R.S. Jallad, N.R. Musolino, L.R. Salgado, M.D. Bronstein, Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin. Endocrinol. 63(2), 168\u2013175 (2005)","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"2766_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2265.2007.03067.x","volume":"68","author":"M Andries","year":"2008","unstructured":"M. Andries, D. Glintborg, A. Kvistborg, C. Hagen, M. Andersen, A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin. Endocrinol. 68(3), 473\u2013480 (2008)","journal-title":"Clin. Endocrinol."},{"issue":"6","key":"2766_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"M. Mercado, F. Borges, H. Bouterfa, T.-C. Chang, A. Chervin, A.J. Farrall, A. Patocs, S. Petersenn, J. Podoba, M. Safari, J. Wardlaw, A prospective, multicenter study to investigate the efficacy, safety and tolerability of octreotide LAR (longacting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. 66(6), 859\u2013868 (2007)","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"2766_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2265.2011.04106.x","volume":"75","author":"Z Karaca","year":"2011","unstructured":"Z. Karaca, F. Tanriverdi, G. Elbuken, I. Cakir, H. Donmez, A. Selcuklu, A. Durak, H. Dokmetas, R. Colak, K. Unluhizarci, F. Kelestimur, Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly. Clin. Endocrinol. 75(5), 678\u2013684 (2011)","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"2766_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Res\u00e9ndiz, M. Ruffin, Y. Chen, M. Sheppard; Pasireotide C2305 Study Group, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99(3), 791\u20139 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2766_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","volume":"13","author":"S Melmed","year":"2010","unstructured":"S. Melmed, D. Cook, J. Schopohl, M.I. Goth, K.S. Lam, J. Marek, Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13(1), 18\u201328 (2010)","journal-title":"Pituitary"},{"issue":"5","key":"2766_CR32","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1507\/endocrj.EJ12-0417","volume":"60","author":"A Shimatsu","year":"2013","unstructured":"A. Shimatsu, A. Teramoto, N. Hizuka, K. Kitai, J. Ramis, K. Chihara, Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr. J. 60(5), 651\u2013663 (2013)","journal-title":"Endocr. J."},{"issue":"2","key":"2766_CR33","first-page":"187","volume":"9","author":"A Buliman","year":"2016","unstructured":"A. Buliman, L.G. Tataranu, V. Ciubotaru, T.L. Cazac, C. Dumitrache, The multimodal management of GH-secreting pituitary adenomas: predictive factors, strategies and outcomes. J. Med Life 9(2), 187\u201392 (2016)","journal-title":"J. Med Life"},{"issue":"2","key":"2766_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","volume":"23","author":"S Petersenn","year":"2020","unstructured":"S. Petersenn, A. Houchard, C. Sert, P.J. Caron; PRIMARYS Study Group, Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 23(2), 171\u2013181 (2020)","journal-title":"Pituitary"},{"issue":"7","key":"2766_CR35","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1210\/jc.2003-030110","volume":"88","author":"R Cozzi","year":"2003","unstructured":"R. Cozzi, R. Attanasio, M. Montini, G. Pagani, G. Lasio, S. Lodrini, M. Barausse, M. Albizzi, D. Dallabonzana, A.M. Pedroncelli, Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab. 88(7), 3090\u20133098 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1-2","key":"2766_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.mce.2007.11.024","volume":"286","author":"A Ben-Shlomo","year":"2008","unstructured":"A. Ben-Shlomo, S. Melmed, Somatostatin agonists for treatment of acromegaly. Mol. Cell Endocrinol. 286(1-2), 192\u2013198 (2008)","journal-title":"Mol. Cell Endocrinol."},{"issue":"2","key":"2766_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","volume":"71","author":"A Colao","year":"2009","unstructured":"A. Colao, R.S. Auriemma, A. Rebora, M. Galdiero, E. Resmini, F. Minuto, G. Lombardi, R. Pivonello, D. Ferone, Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin. Endocrinol. 71(2), 237\u2013245 (2009)","journal-title":"Clin. Endocrinol."},{"issue":"4","key":"2766_CR38","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1210\/jc.2005-2347","volume":"91","author":"R Cozzi","year":"2006","unstructured":"R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio, S. Lodrini, P. Doneda, L. Cortesi, G. Pagani, Primary treatment of acromegaly with octreotide LAR: a longterm (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J. Clin. Endocrinol. Metab. 91(4), 1397\u20131403 (2006)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"2766_CR39","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4158\/EP.14.7.846","volume":"14","author":"R Attanasio","year":"2008","unstructured":"R. Attanasio, R. Lanzi, M. Losa, F. Valentini, F. Grimaldi, E. De Menis, M.V. Davi, C. Battista, R. Castello, N. Cremonini, P. Razzore, F. Rosato, M. Montini, R. Cozzi, Effects of lanreotide Autogel on growth hormone, insulin like growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr. Pract. 14(7), 846\u2013855 (2008)","journal-title":"Endocr. Pract."},{"issue":"4","key":"2766_CR40","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1365-2265.2005.02233.x","volume":"62","author":"SS Damjanovic","year":"2005","unstructured":"S.S. Damjanovic, A.N. Neskovic, M.S. Petakov, V. Popovic, D. Macut, P. Vukojevic, M.M. Joksimovic, Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin. Endocrinol. 62(4), 410\u20137 (2005)","journal-title":"Clin. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02766-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T05:32:18Z","timestamp":1631597538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02766-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2766"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02766-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K.Z.B.M., C.L.S., and X.A. have nothing to declare. M.R.G. has received lecture fees from Novartis, Ipsen, Pfizer and Crinetics, has participated on advisory boards of Novartis, Ipsen and Crinetics, and has served as principal investigator in clinical trials of Novartis and Crinetics. L.K. has received lecture fees and has participated as a coinvestigator in clinical trials of Novartis and Ipsen. C.L.B. has received lecture fees from Novartis and Ipsen and has served as principal investigator in clinical trials of Novartis and Crinetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committees of the Universidade Federal do Parana and Universidade Federal do Rio de Janeiro and conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}